NEW YORK, Nov. 9 (GenomeWeb News) - Novavax and CombiMatrix plan to develop a technique monitoring vaccine production, Acacia Research said today.
Traditional flu-vaccine development and production is too slow to accommodate rapidly evolving flu strains, the company said. CombiMatrix's technique improves the process by tracking the genetic fidelity of the genes encoding the vaccine.
CombiMatrix and Novavax will test the method's efficacy on Novavax's VLP process for producing H5N1 bird flu vaccine.
Financial details were not disclosed.